BTIG analyst David Larsen raised the firm’s price target on BrightSpring Health (BTSG) to $41 from $30 and keeps a Buy rating on the shares after its Q3 earnings beat. The higher revenue guidance continues to be driven by solid momentum in Pharmacy, with infusion and specialty growing at a very rapid pace, and the firm continues to be impressed by BrightSpring’s broad strength and growth across the entire business, driven by high quality care, a growing market, and thoughtful and strategic leadership, the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BTSG:
- BrightSpring Health price target raised to $42 from $35 at UBS
- BrightSpring Health Services, Inc.: Strong Financial Performance and Growth Prospects Justify Buy Rating
- BrightSpring Health Services, Inc.: Strong Growth Prospects and Strategic Leverage Improvement Reinforce Buy Rating
- BrightSpring Health Services Reports Strong Q3 2025 Results
- BrightSpring Health Services: Strong Fundamentals and Promising 2026 Outlook Justify Buy Rating